Trellis Bioscience, Inc.
Trellis Bioscience is a biotechnology company leveraging its proprietary CellSpot™ technology to discover and develop native human monoclonal antibodies for the treatment and prevention of infectious diseases and cancer. The company focuses on targeting bacterial, viral, and cancer indications with a portfolio of therapeutics that have demonstrated efficacy in model systems. Trellis aims to harness the human immune system's natural antibody responses to create safer and more effective treatments, with a strong emphasis on disrupting biofilms, combating antimicrobial resistance, and targeting tumor-associated antigens.
Industries
Nr. of Employees
medium (51-250)
Trellis Bioscience, Inc.
702 Marshall Street, Suite 301, Redwood City, CA 94063
Patents
Immunogen providing an extended protective lifetime against respiratory syncytial virus (RSV) and vaccines thereof
US-12246063-B2
View DetailsConformational epitopes in respiratory syncytial virus G protein central conserved region
US-11773143-B2
View DetailsMonoclonal antibodies targeting killer immunoglobulin-like receptor (KIR) family signaling
US-11725055-B2
View DetailsAntibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
US-11246928-B2
View Details
Immunogen providing an extended protective lifetime against respiratory syncytial virus (RSV) and vaccines thereof
US-12246063-B2
View DetailsConformational epitopes in respiratory syncytial virus G protein central conserved region
US-11773143-B2
View DetailsMonoclonal antibodies targeting killer immunoglobulin-like receptor (KIR) family signaling
US-11725055-B2
View DetailsAntibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
US-11246928-B2
View DetailsProducts
TRL1068 (calpurbatug)
Native human monoclonal antibody that binds a conserved biofilm scaffolding protein family to disrupt bacterial biofilm and restore antibiotic susceptibility.
TRL345
High-affinity native human monoclonal antibody against a conserved site on cytomegalovirus (glycoprotein B) with demonstrated neutralization across clinical isolates and activity in placental/ex vivo models.
CF404 (pan-influenza antibody cocktail)
Cocktail of three monoclonal antibodies targeting conserved regions across influenza A and B strains, developed for broad-spectrum post-infection efficacy.
TRL3D3
Native human monoclonal antibody targeting a conserved region of the RSV G glycoprotein with direct antiviral activity and modulation of immune effects associated with the G protein.
TRL10001 (anti-ALK)
High-affinity human monoclonal antibody recognizing the extracellular domain of ALK that internalizes rapidly in ALK-expressing tumor cells, assessed for antibody–drug conjugate opportunities.
TRL1068 (calpurbatug)
Native human monoclonal antibody that binds a conserved biofilm scaffolding protein family to disrupt bacterial biofilm and restore antibiotic susceptibility.
TRL345
High-affinity native human monoclonal antibody against a conserved site on cytomegalovirus (glycoprotein B) with demonstrated neutralization across clinical isolates and activity in placental/ex vivo models.
CF404 (pan-influenza antibody cocktail)
Cocktail of three monoclonal antibodies targeting conserved regions across influenza A and B strains, developed for broad-spectrum post-infection efficacy.
TRL3D3
Native human monoclonal antibody targeting a conserved region of the RSV G glycoprotein with direct antiviral activity and modulation of immune effects associated with the G protein.
TRL10001 (anti-ALK)
High-affinity human monoclonal antibody recognizing the extracellular domain of ALK that internalizes rapidly in ALK-expressing tumor cells, assessed for antibody–drug conjugate opportunities.
Expertise Areas
- Monoclonal antibody discovery from human memory B-cells
- Multiplexed antigen screening and epitope mapping
- Preclinical infectious disease models and biofilm therapeutics
- Clinical trial design and early-phase execution
Key Technologies
- Single-cell multiplexed B-cell screening
- Computerized high-throughput microscopy
- Multiplexed antigen binding assays
- X-ray crystallography
News & Updates
An article discussing the importance of biofilm disruption and Trellis Bioscience's development of TRL1068 as a novel anti-infective agent.
Publication of a Phase 1 clinical study demonstrating the efficacy of TRL1068 in disrupting bacterial biofilms in patients with prosthetic joint infections.
Development of a broad-spectrum human monoclonal antibody cocktail (TRL404) targeting influenza strains, including H5N1, with efficacy in mice.
An article on how TRL1068 disrupts bacterial biofilms, potentially transforming treatment of resistant infections.
Publication of a Phase 1 clinical study demonstrating the efficacy of TRL1068 in disrupting bacterial biofilms in patients with prosthetic joint infections.
A collection of articles discussing the mechanisms by which respiratory syncytial virus (RSV) evades the immune system and the development of therapeutics targeting RSV.
An article discussing the importance of biofilm disruption and Trellis Bioscience's development of TRL1068 as a novel anti-infective agent.
Publication of a Phase 1 clinical study demonstrating the efficacy of TRL1068 in disrupting bacterial biofilms in patients with prosthetic joint infections.
Development of a broad-spectrum human monoclonal antibody cocktail (TRL404) targeting influenza strains, including H5N1, with efficacy in mice.
An article on how TRL1068 disrupts bacterial biofilms, potentially transforming treatment of resistant infections.
Publication of a Phase 1 clinical study demonstrating the efficacy of TRL1068 in disrupting bacterial biofilms in patients with prosthetic joint infections.
A collection of articles discussing the mechanisms by which respiratory syncytial virus (RSV) evades the immune system and the development of therapeutics targeting RSV.